GOLSEEK-4: A phase 3 trial of golcadomide with rituximab in people with relapsed or refractory follicular lymphoma
This trial aims to see how effective golcadomide in combination with rituximab is when compared to standard treatment in people with follicular lymphoma which has returned after (relapsed) or not responded (refractory) to treatment
You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT06911502
Trial aim and background
The aim of this trial is to see how safe and effective the treatment golcadomide is when given with rituximab when compared to standard treatment in people with relapsed or refractory follicular lymphoma.
Who can enter
Adults with grade 1, 2 or 3a follicular lymphoma who have relapsed or not responded to one other line of treatment may be eligible for this trial.
Locations
Recruitment is taking place at the following UK locations:
- Canterbury
- Cringleford
- Manchester
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at:
https://clinicaltrials.gov/study/NCT06911502
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.